TD Cowen analyst Joshua Jennings lowered the firm’s price target on Insulet to $300 from $350 and keeps an Outperform rating on the shares. The firm posted another solid quarter which enabled another round of sales guidance raises with full-year revenue growth now expected at 22-25%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PODD: